LENZ Therapeutics (NASDAQ:LENZ) Upgraded by Zacks Research to “Hold” Rating

LENZ Therapeutics (NASDAQ:LENZ) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Other research analysts also recently issued reports about the company. Piper Sandler cut their price target on LENZ Therapeutics from $12.00 to $7.00 and set a “neutral” rating on the stock in a report on Wednesday. Citigroup restated a “buy” rating on shares of LENZ Therapeutics in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating on shares of LENZ Therapeutics in a research report on Tuesday, July 7th. Finally, Weiss Ratings downgraded LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $28.80.

LENZ Therapeutics Stock Performance

NASDAQ LENZ opened at $4.73 on Thursday. The company has a market cap of $148.62 million, a PE ratio of -1.16 and a beta of 0.65. The firm’s 50 day moving average price is $5.64 and its 200-day moving average price is $9.01. LENZ Therapeutics has a 52-week low of $4.53 and a 52-week high of $50.40.

LENZ Therapeutics (NASDAQ:LENZ) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($1.02) EPS for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.03. The company had revenue of $5.49 million during the quarter, compared to the consensus estimate of $2.38 million. LENZ Therapeutics had a negative net margin of 586.74% and a negative return on equity of 53.39%. On average, analysts forecast that LENZ Therapeutics will post -4.18 earnings per share for the current fiscal year.

Institutional Trading of LENZ Therapeutics

A number of institutional investors have recently bought and sold shares of LENZ. C WorldWide Group Holding A S acquired a new stake in shares of LENZ Therapeutics during the fourth quarter worth $8,000,000. UBS Group AG grew its holdings in shares of LENZ Therapeutics by 30.8% during the fourth quarter. UBS Group AG now owns 1,571,738 shares of the company’s stock valued at $25,148,000 after buying an additional 370,122 shares during the last quarter. Y Intercept Hong Kong Ltd increased its position in shares of LENZ Therapeutics by 290.8% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 158,715 shares of the company’s stock valued at $1,452,000 after acquiring an additional 118,100 shares during the period. Granahan Investment Management LLC increased its position in shares of LENZ Therapeutics by 125.2% in the 4th quarter. Granahan Investment Management LLC now owns 431,100 shares of the company’s stock valued at $6,898,000 after acquiring an additional 239,703 shares during the period. Finally, Blue Owl Capital Holdings LP purchased a new position in LENZ Therapeutics in the 4th quarter worth $2,400,000. 54.32% of the stock is currently owned by institutional investors and hedge funds.

LENZ Therapeutics News Summary

Here are the key news stories impacting LENZ Therapeutics this week:

• Positive Sentiment: LENZ’s VIZZ prescriptions reportedly increased more than 45% month over month in July, while the company outlined telehealth and national television initiatives intended to support broader product adoption. Lenz outlines July telehealth and national TV push as VIZZ scripts rise over 45% month over month
• Positive Sentiment: HC Wainwright maintained its Buy rating and raised its Q3 2026 EPS forecast to a loss of $1.02 from a loss of $1.15. It also improved its FY2026 estimate to a loss of $4.35 from a loss of $4.74, suggesting somewhat better near-term expectations.
• Neutral Sentiment: The company’s Q2 2026 earnings call focused on VIZZ’s launch progress and commercialization efforts, giving investors additional information about early demand and the strategy for expanding the product’s reach. LENZ Therapeutics, Inc. Q2 2026 Earnings Call Summary
• Negative Sentiment: Bank of America downgraded LENZ on concerns that VIZZ’s launch may be slower than expected, a significant issue for a company whose valuation depends on successful commercial execution. Lenz drops as BofA downgrades on a slower VIZZ launch
• Negative Sentiment: HC Wainwright reduced its longer-term EPS forecasts for FY2027 through FY2029 and sharply cut FY2030 EPS to $0.63 from $2.72. Although the firm remains bullish, the revisions imply a slower path to profitability and weigh on the stock’s long-term outlook.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.